How to choose between acotinib/acalabrutinib and zanubrutinib

Acotinib (acalatinib), as a second-generation BTK inhibitor, combines with BTK through a less reactive butynamide group. It has high target selectivity and relatively low incidence of adverse reactions and toxicity. This feature allows acotinib to target more accurately during treatment and reduce unnecessary side effects.

Zanubrutinib is another highly effective BTK inhibitor, and has also shown a highly effective inhibitory effect on BTK. By optimizing the molecular structure, it achieves complete, long-lasting and precise inhibition of the BTK target. This drug has also been verified through rigorous clinical trials and has shown good efficacy and safety.

Acotinib is indicated primarily for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, as well as adult patients with chronic lymphocytic leukemia (CLL) or small cell lymphoma (SLL). In clinical trials, acotinib showed a significant overall response rate, providing a new treatment option for these patients.

The indications of zanubrutinib also cover the treatment of a variety of lymphomas, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL), etc. In terms of efficacy, zanubrutinib has also shown impressive results.

In terms of safety, the incidence of adverse reactions and toxicity of acotinib is relatively low. Common adverse reactions may include anemia, neutropenia, etc., but usually these reactions are controllable. Zanubrutinib also has a good safety profile, but may cause different side effects, such as radiation dermatitis. Therefore, the patient's specific situation and tolerance for potential side effects need to be taken into consideration when selecting a drug.

Patients should first choose the appropriate drug based on their type of disease. Although both acotinib and zanubrutinib are suitable for the treatment of lymphoma, their specific indications may be different. The patient's physical condition, age, gender and other factors may affect the choice of drug. For example, younger patients may be more tolerant of certain side effects, while older patients may need to pay more attention to the safety of the drug.